openPR Logo

Press Releases from myriamed GmbH (8 total)

myriamed is now a member of the Network for Pharma Solutions

We are proud to announce that myriamed is now a member of the Network for Pharma Solutions (NetPhaSol). NetPhaSol is a cooperation network focusing on drug discovery & development. It serves as a platform for research, development and marketing of new products, technologies and services in drug development. About myriamed: myriamed has unique expertise in research and development of human induced pluripotent stem cells (iPSC), including genome edited lines, and in

Helping to accelerate the development of novel drugs against Covid-19 disease

Even though vaccines against Covid-19 will be available soon, artificial herd immunity via vaccination will probably not reached until the end of 2021. Thus, the current fight against Covid-19 disease heavily relies on already available drugs. Unfortunately, there is hardly any drug that fights the disease effectively. Cortisone based therapeutics are currently the ones used most frequently and most successfully. The originally promising drug Remdesivir, which has been approved for the

myriamed’s myrPlates are now also available from ZAGENO

We are proud to announce that myriamed’s myrPlates are now also available in the ZAGENO life science, e-commerce marketplace. myrPlates can be used for the generation of engineered human tissues. By parallel culture of up to 48 tissues in one myrPlate, e.g. contractile heart muscles or skeletal muscles can be obtained to serve numerous applications, such as drug screening and disease modelling. About myriamed: myriamed has unique expertise in research and development

Generation of Engineered Human Myocardium using myriamed myrPlates

In STAR Protocols Tibury et al. describe a robust method for the generation of engineered human myocardium (EHM) from pluripotent stem cells (PSCs) in 48 well myriamed myrPlates under defined, serum-free conditions (DOI: 10.1016/j.xpro.2020.100032). By parallel culture of up to 48 EHM in one myrPlate, contractile heart muscle can be obtained to serve numerous applications, such as drug screening and disease modelling, which are also offered by myriamed. The described protocol has

myriamed is now a member of Ksilink

We proudly announce that myriamed GmbH is now a member of the Ksilink association. The public private association is aiming to render drug development faster and more efficient, heading towards precision medicine. Together with its partners Ksilink develops and applies patient based disease models for phenotypic drug discovery purposes, and generates novel molecular entities for diseases with a high medical need, such as cardiac disorders. Ksilink is covering the entire

myriamed supports local soccer club

myriamed supports the local soccer club SV Puma with a small donation to help them buy new sportswear. We hope that the COVID-19 pandemic will be over soon and team sports can take place again. About myriamed: myriamed has unique expertise in research and development of human induced pluripotent stem cells (iPSC), including genome edited lines, and in the controlling of their fate as to the differentiation into defined cellular lineages

Bioengineered Neuronal Organoids are now commercially available from myriamed

Zafeiriou et al. report the directed self-organization of human induced pluripotent stem cells in a collagen hydrogel towards a highly interconnected neuronal network at a macroscale tissue format (Bioengineered Neuronal Organoids: BENOs): https://lnkd.in/e6zQeCJ BENOs are now commercially available from myriamed. Get in touch for details: https://bit.ly/2Di5ELG myriamed GmbH Rudolf-Wissell-Str. 28a 37079 Göttingen Tel.: +49 551 28878-170 Email: info@myriamed.com Web: www.myriamed.com myriamed – the drug development accelerator Separating the pharmacological wheat from the chaff is the primary goal of myriamed.

myriamed supports COVID-19 research of the University Medical Center Göttingen …

We support the current research efforts on COVID-19 at the Institute of Pharmacology and Toxicology of the UMG by providing iPSC-derived cardiomyocytes (myrCell-Cardio) and specially designed multi-well plates (myrPlates) for culturing engineered human myocardium as a model system to identify potentially deadly cardiac disorders in patients with COVID-19 infections. To learn more about the products please contact us: bit.ly/2Di5ELG myriamed GmbH Rudolf-Wissell-Str. 28a 37079 Göttingen Tel.: +49 551 28878-170 Email: info@myriamed.com Web: www.myriamed.com myriamed – the drug development

Go To Page:   1 2 3 4 5 6 7 8 9 10